A collaboration agreement to augment national surveillance infrastructure in the USA to track the emergence and prevalence of novel strains of SARS-CoV-2 was announced.
With support from the US Centers for Disease Control and Prevention (CDC), llumina, Inc., and Helix announced the combination of sequencing technology, expertise, and a national COVID-19 testing footprint would significantly expand the USA’s existing surveillance efforts to detect and characterize emerging variants of the SARS-CoV-2 betacoronavirus.
Collaboration Launches to Assess the Prevalence of Coronavirus Variant
Number of U.S. Adults Willing to Take COVID-19 Vaccine Down
Findings based on a biweekly survey conducted from April through December
Two-Thirds of Lupus Patients Likely to Take COVID-19 Vaccine
However, national survey uncovered racial differences in uptake, safety concerns
Pandemic-Related MMR Vaccine Decline Persists
Authors say catch-up strategies are necessary to ensure young children receive preventive care
AAP Outlines Principles Guiding School COVID-19 Policies
Academy says opening schools generally does not significantly increase community transmission, but mirrors community transmission
Vast Majority of Mild COVID-19 Patients Lose Sense of Smell
Nearly one-quarter of affected patients report lack of recovery at 60 days
Psychological Distress Increased in U.S. During COVID-19
Numbers of people who experienced serious psychological distress over 30 days during pandemic similar to that in entire year prior to pandemic
China Delays Allowing Experts to Study Start of Pandemic
Experts are expected to visit the city of Wuhan, where it is believed COVID-19 first emerged